Skip to main content

Navigation group

Type at least 3 characters
1,267 articles

Articles

Brief Research Report

Published on 01 Feb 2023

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

in Multiple Sclerosis and Neuroimmunology

  • Pilar Santiago-Setien
  • Cristina Barquín-Rego
  • Paula Hernández-Martínez
  • María Ezquerra-Marigomez
  • Marta Torres-Barquin
  • Cristina Menéndez-Garcia
  • Fernando Uriarte
  • Yésica Jiménez-López
  • Mercedes Misiego
  • Jose Ramón Sánchez de la Torre
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
Frontiers in Immunology
doi 10.3389/fimmu.2023.1086028
  • 5,016 views
  • 2 citations